Greiner Bio-One Expands Site in Kremsmünster

Greiner Bio-One is further expanding its site in Kremsmünster through an investment totaling EUR 9.3 million. “The new development will provide maximum flexibility in terms of how we use the space, enabling us to further optimize our work processes,” says Rainer Perneker, Division Director of Greiner Bio-One International. Additional stories will be added to the... Read more

Product Launch: MiniCollect® Lancelino Safety Lancets

  The MiniCollect® Lancelino Safety Lancet from Greiner Bio-One brings more variety to the MiniCollect® product line. The MiniCollect® Lancelino is automatically activated by pressing on the puncture site and includes five needle gauge and blade options. The new MiniCollect® Lancelino Safety Lancets offer the following advantages: • Easy activation by pressing on the puncture... Read more

Video Release — Microscopic Predator Attack Scene Wins First Place in Annual Nikon Small World in Motion Competition

MELVILLE, N.Y., Dec. 09, 2015 (GLOBE NEWSWIRE) — Nikon Instruments Inc. today unveiled the winners of the fifth annual Nikon Small World in Motion Photomicrography Competition, awarding First Place to veteran winner Wim van Egmond of the Micropolitan Museum in The Netherlands. Judges were impressed with the thrilling video van Egmond captured of a ciliate... Read more

GE Healthcare to Connect 500,000 Imaging Machines with Announcement of GE Health Cloud and Apps

CHICAGO, Ill. – November 29, 2015 – The GE Health Cloud[1] was unveiled today at the 101st annual Radiological Society of North America (RSNA) meeting in Chicago. Designed exclusively for the healthcare industry, the new cloud ecosystem and its applications will connect radiologists and clinicians to speed, efficiency and collaboration across care pathways and multidisciplinary... Read more

Discovery RT Designed to Improve Accuracy for Radiation Therapy Planning

SAN ANTONIO, TEXAS – October 19, 2015 – GE Healthcare, a division of General Electric Company (NYSE: GE), is introducing the DiscoveryTM RT*, a new advanced radiation therapy planning computed tomography (CT) system at the 57th Annual American Society for Radiation Oncology (ASTRO) Meeting in San Antonio, Texas. http://www.genewsroom.com/press-releases/discovery-rt-designed-improve-accuracy-radiation-therapy-planning-282063 Read more

A Pacific Biosciences lança uma nova plataforma de sequenciamento baseada em sua tecnologia SMRT

MENLO PARK, Calif., 2015-10-03 02:39 CEST (GLOBE NEWSWIRE) — A Pacific Biosciences of California, Inc. (NASDAQ:PACB), pioneira e líder em sequenciamento de leitura de longa duração usando sua tecnologia Single Molecule, Real-Time (Molécula Única, em Tempo Real – SMRT(R)), anunciou hoje que lançou uma nova plataforma de sequenciamento de ácido nucleico. O sistema Sequel(TM) proporciona... Read more

Pacific Biosciences lanza una nueva plataforma de secuenciación basada en su tecnología SMRT

MENLO PARK, California, 2015-10-02 23:23 CEST (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ:PACB, pionera y líder en secuenciación de lecturas largas que utiliza tecnología de una sola molécula en tiempo real (Single Molecule, Real-Time, SMRT(R)), anunció hoy el lanzamiento de una nueva plataforma de secuenciación de ácidos nucleicos.El Sequel(TM)System ofrece un rendimiento y... Read more

GE HEALTHCARE ANNOUNCES $300 MILLION COMMITMENT TO SUPPORT EMERGING MARKET HEALTH

New York City, NY – September 23, 2015 – GE Healthcare, the $18 billion healthcare technology division of GE (NYSE: GE), today announced the creation of a new business unit, Sustainable Healthcare Solutions (SHS), that will develop high-value, low-cost technologies and healthcare delivery solutions across multiple care settings. http://www.genewsroom.com/press-releases/ge-healthcare-announces-300-million-commitment-support-emerging-market-health-281784 Read more

GE Healthcare commends DEA decision that will make DaTscan™ (Ioflupane I 123 Injection) more available to patients who may have Parkinsonism

GE Healthcare (NYSE:GE) is pleased to announce that the US Drug Enforcement Administration (DEA) has removed the compound ioflupane I 123 from the schedules of the Controlled Substance Act, which has resulted in the descheduling of DaTscan™ (Ioflupane I 123 Injection). http://www.genewsroom.com/press-releases/ge-healthcare-commends-dea-decision-will-make-datscan%E2%84%A2-ioflupane-i-123-injection-more Read more